Gepirone Extended-Release: First Approval.
Drugs
; 83(18): 1723-1728, 2023 Dec.
Article
en En
| MEDLINE
| ID: mdl-38079093
ABSTRACT
Gepirone HCL extended-release (gepirone ER; EXXUA™), an oral, selective serotonin (5HT)1A receptor agonist formulated for once-daily administration, has been developed by Fabre-Kramer Pharmaceuticals, Inc. for the treatment of psychiatric disorders, including major depressive disorder (MDD). In September 2023, gepirone ER was approved in the USA for the treatment of adults with MDD. This article summarizes the milestones in the development of gepirone ER leading to this first approval for the treatment of adults with MDD.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Trastorno Depresivo Mayor
Límite:
Adult
/
Humans
Idioma:
En
Revista:
Drugs
Año:
2023
Tipo del documento:
Article
País de afiliación:
Nueva Zelanda